<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356642</url>
  </required_header>
  <id_info>
    <org_study_id>TPD102031</org_study_id>
    <nct_id>NCT00356642</nct_id>
  </id_info>
  <brief_title>Study Of Single And Ten Day Repeat Atopical Applications Of GW842470X Cream On The Skin Of Patients With Atopic Dermatitis</brief_title>
  <official_title>A Randomised, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Ten Day Repeat Topical Applications of GW842470X Cream on the Skin of Patients With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study of this study is to investigate the safety, tolerability and
      pharmacokinetics of GW842470X in patients with atopic dermatitis. GW842470X is an inhibitor
      of phosphodiesterase 4 (PDE4).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2005</start_date>
  <completion_date type="Actual">December 21, 2005</completion_date>
  <primary_completion_date type="Actual">December 21, 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with abnormal physical examination findings</measure>
    <time_frame>Up to Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal blood pressure</measure>
    <time_frame>Up to Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal heart rate</measure>
    <time_frame>Up to Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal 12-lead ECG assessment</measure>
    <time_frame>Up to Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal findings on lead II cardiac monitoring</measure>
    <time_frame>Up to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal clinical laboratory tests</measure>
    <time_frame>Up to Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 12 hours on Day 1, pre-dose on Days 3, 5, 7, 9 and pre-dose, 1, 2, 4, 6, 8, 12 , 24, 36 and 48 hours post-dose on Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 12 hours on Day 1, pre-dose on Days 3, 5, 7, 9 and pre-dose, 1, 2, 4, 6, 8, 12 , 24, 36 and 48 hours post-dose on Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to max concentration and terminal half-life</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 12 hours on Day 1, pre-dose on Days 3, 5, 7, 9 and pre-dose, 1, 2, 4, 6, 8, 12 , 24, 36 and 48 hours post-dose on Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCORAD</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSA determination</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical photography</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of barrier function using trans-epidermal water loss (TEWL)</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin biopsy (biomarkers CD4+, CD8+, eosinophils, total IgE)</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Single dose 1 cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with body surface area (BSA) disease involvement between 10 and 15% will be included. Subjects will receive either 100 milligrams (mg) GW842470X or placebo in a ratio of 2:1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat dose 1 cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with BSA disease involvement between 10 and 15% will be included. Subjects will receive either 100-150 mg GW842470X or placebo in a ratio of 3:1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat dose 2 cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with BSA disease involvement between 30 and 40% will be included. Subjects will receive either 300-400 mg GW842470X or placebo in a ratio of 3:1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat dose 3 cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with BSA disease involvement &gt;=50% will be included. Subjects will receive either 500-1000 mg GW842470X or placebo in a ratio of 2:1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW842470X</intervention_name>
    <description>GW842470X will be available as a yellow smooth water-in-oil cream.</description>
    <arm_group_label>Repeat dose 1 cohort</arm_group_label>
    <arm_group_label>Repeat dose 2 cohort</arm_group_label>
    <arm_group_label>Repeat dose 3 cohort</arm_group_label>
    <arm_group_label>Single dose 1 cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.</description>
    <arm_group_label>Repeat dose 1 cohort</arm_group_label>
    <arm_group_label>Repeat dose 2 cohort</arm_group_label>
    <arm_group_label>Repeat dose 3 cohort</arm_group_label>
    <arm_group_label>Single dose 1 cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Atopic dermatitis patients (moderate to severe) who are otherwise healthy.

          -  BMI range 18.5-29.9m2 at least 2 index lesions and BSA involvement &gt;10%.

          -  14 day washout of current therapy.

        Exclusion criteria:

          -  Patients who have had systemic treatment for atopic dermatitis or other topical or
             transdermal treatments (such as nicotine, hormone replacement therapies) within 14
             days prior to first application of study medication and/or topical treatment with tar
             or any treatment with corticosteroids within 14 days prior to first application except
             1% hydrocortisone.

          -  Patients must not present with any systemic disorders or active skin disease other
             than atopic dermatitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/TPD102031?search=study&amp;search_terms=102031#rs</url>
    <description>Results for study 102031 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2006</study_first_submitted>
  <study_first_submitted_qc>July 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2006</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PK</keyword>
  <keyword>GW842470X</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>PD</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

